Patent ID: 11873532
Assignee: DECIPHER BIOSCIENCES, INC.
Field: Measurement (Instruments)
Classification: CPC C  G | IPC C  G

Claim 0:
1. A method comprising:
a) providing a biological sample from a subject having prostate cancer;
b) extracting nucleic acids from the biological sample;
c) detecting the presence or expression level in the biological sample for targets CDC20, KIF2C, PHGDH, NUF2, CENPF, EXO1, UBE2T, RRM2, MLPH, GPR160, CCNB1, CXXC5, PTTG1, FGFR4, FOXC1, ESR1, ANLN, BLVRA, EGFR, ACTR3B, NAT1, MYC, SFRP1, MELK, BAG1, CEP55, MKI67, TMEM45B, PGR, MDM2, KRT5, FOXA1, ORC6, CDH3, ERBB2, GRB7, CDC6, MAPT, BIRC5, KRT14, KRT17, TYMS, NDC80, SLC39A6, BCL2, CCNE1, MIA, MYBL2, UBE2C, and MMP11;
d) subtyping the prostate cancer in the subject according to a genomic subtyping classifier based on the presence or expression levels of the plurality of targets, wherein said subtyping comprises assigning the prostate cancer to a luminal B subtype; and
e) administering a treatment comprising androgen deprivation therapy to a subject who has the luminal B subtype.